<Disease><Name>GAUCHER DISEASE TYPE I</Name><Synonym /><OMIM><Number>230800</Number><URL>http://omim.org/entry/230800</URL></OMIM><Orphanet><Number>77259</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=77259</URL></Orphanet><Protein><Number>Lysosomal acid glucosylceramidase</Number><URL>http://www.uniprot.org/uniprot/P04062</URL></Protein><ExPASy><Number>3.2.1.45</Number><URL>http://enzyme.expasy.org/EC/3.2.1.45</URL></ExPASy><Gene>1q22</Gene><ICD>E75.2</ICD><Summary>1:600 (&gt;350 patients) ;autosomal recessive ;type I is mainly found in Ashkenazic Jews ;3 types: ;- chronic/adult (I) MIM 230800 ;- acute/infantile(II) MIM 230900 ;- juvenile (III) MIM 231000;- cardiovascular (IIIC) MIM 231005</Summary><Symptoms><symtomp><id>2347</id><symptom>anemia</symptom><category>IMMUNE OR HEMATOLOGIC SYSTEM | LABORATORY FINDINGS</category></symtomp><symtomp><id>2129</id><symptom>arthritis</symptom><category>SKELATAL DEFECT | SKELETAL DEFECT</category></symtomp><symtomp><id>2130</id><symptom>bleeding tendencies, hemorrhages / bleeding tendencies, hemorrhage</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2288</id><symptom>bone fractures / pathological fractures</symptom><category>SKELETAL DEFECT</category></symtomp><symtomp><id>1997</id><symptom>cirrhosis or fibrosis of liver</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>2564</id><symptom>DNA / deoxyribonucleic acid</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>1882</id><symptom>growth retardation, poor growth</symptom><category>GENERAL TOPICS | GENERAL TOPICS</category></symtomp><symtomp><id>2449</id><symptom>heart involvement</symptom><category>CARDIOVASCULAR SYSTEM</category></symtomp><symtomp><id>1994</id><symptom>hepatomegaly (large liver)</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>2169</id><symptom>hyperpigmentation</symptom><category>SKIN</category></symtomp><symtomp><id>1917</id><symptom>neurological deterioration / neurologic deterioration</symptom><category>GENERAL TOPICS | NERVOUS SYSTEM</category></symtomp><symtomp><id>2038</id><symptom>neutropenia (decreased neutrophils)</symptom><category>IMMUNE OR HEMATOLOGIC SYSTEM | LABORATORY FINDINGS</category></symtomp><symtomp><id>2506</id><symptom>onset, adolescent / adolescence</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1915</id><symptom>onset, adulthood / adoulthood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2507</id><symptom>onset, childhood / childhood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2358</id><symptom>pain, bones or joints / pain bones</symptom><category>GENERAL TOPICS | SKELATAL DEFECT | SKELETAL DEFECT</category></symtomp><symtomp><id>2268</id><symptom>pigmentation, skin and sclera</symptom><category>SKIN</category></symtomp><symtomp><id>3696</id><symptom>pulmonary hypertension</symptom><category>CARDIOVASCULAR SYSTEM | LUNG OR RESPIRATORY SYSTEM</category></symtomp><symtomp><id>2143</id><symptom>respiratory insufficiency / respiratory failure</symptom><category>LUNG OR RESPIRATORY SYSTEM</category></symtomp><symtomp><id>3800</id><symptom>restrictive lung disease</symptom><category>LUNG OR RESPIRATORY SYSTEM</category></symtomp><symtomp><id>2342</id><symptom>skeletal changes, skeletal abnormalities</symptom><category>SKELATAL DEFECT | SKELETAL DEFECT</category></symtomp><symtomp><id>2042</id><symptom>splenomegaly (large spleen)</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>3199</id><symptom>thrombopenia, thrombocytopenia</symptom><category>LABORATORY FINDINGS</category></symtomp></Symptoms><Metabolites><metabolite><id>1668</id><name>1-Methylhydantoin</name><specimen>urine</specimen><value /><min>1.00</min><max>11.00</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1825</id><name>1-Methylhydantoin</name><specimen>urine</specimen><value /><min>49.00</min><max>370.00</max><unit>mmol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment /></metabolite><metabolite><id>1172</id><name>bleeding time</name><specimen /><value /><min>3.00</min><max>5.00</max><unit>min</unit><age>no data</age><method /><comment /></metabolite></Metabolites><Literatures><literature><id>7404</id><title>The N370S/R496H genotype in type 1 Gaucher disease - Natural history and implications for pre symptomatic diagnosis and counseling</title><author>Zeid N,</author><journal>Mol Genet Metab Rep</journal><year>2020</year><book /><volume>22</volume><number>0</number><pages>100567</pages><co_aut>et al.</co_aut></literature><literature><id>7951</id><title>Quality of life and psychological functioning of pediatric and young adult patients with Gaucher disease, type 1</title><author>Alioto AG,</author><journal>Am J Med Genet A</journal><year>2020</year><book /><volume>182</volume><number>5</number><pages>1130-1142</pages><co_aut>et al.</co_aut></literature><literature><id>7983</id><title>High risk screening for Gaucher disease in patients with splenomegaly and/or thrombocytopenia in China: 55 cases identified</title><author>Huang Y,</author><journal>Clin Chim Acta</journal><year>2020</year><book /><volume>506</volume><number>0</number><pages>22-27</pages><co_aut>et al.</co_aut></literature><literature><id>7210</id><title>Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease</title><author>Hurvitz N,</author><journal>Int J Mol Sci</journal><year>2019</year><book /><volume>20</volume><number>12</number><pages>E3033</pages><co_aut>et al.</co_aut></literature><literature><id>7211</id><title>Expanding the clinical utility of glucosylsphingosine for Gaucher disease</title><author>Saville JT,</author><journal>J Inherit Metab Dis</journal><year>2019</year><book /><volume>0</volume><number>0</number><pages /><co_aut>et al.</co_aut></literature><literature><id>4116</id><title>The role of cardiac magnetic resonance in assessing the cardiac involvement in Gaucher type 1 patients: morphological and funct</title><author>Roghi A,</author><journal>J Cardiovasc Med (Hagerstown)</journal><year>2017</year><book /><volume>18</volume><number>4</number><pages>244-248</pages><co_aut>et al.</co_aut></literature><literature><id>4121</id><title>A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments</title><author>Stirnemann J,</author><journal>Int J Mol Sci</journal><year>2017</year><book /><volume>18</volume><number>2</number><pages /><co_aut>et al.</co_aut></literature><literature><id>4536</id><title>Gaucher disease epidemiology and natural history: a comprehensive review of the literature</title><author>Nalysnyk L,</author><journal>Hematology. 2017 Mar;22(2):65-73.</journal><year>2017</year><book /><volume>22</volume><number>2</number><pages>65-73</pages><co_aut>et al.</co_aut></literature><literature><id>4537</id><title>Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe</title><author>Belmatoug N,</author><journal>Eur J Intern Med</journal><year>2017</year><book /><volume>37</volume><number>0</number><pages>25-32</pages><co_aut>et al.</co_aut></literature><literature><id>4538</id><title>Gaucher disease: Progress and ongoing challenges</title><author>Mistry PK,</author><journal>Mol Genet Metab</journal><year>2017</year><book /><volume>120</volume><number>1</number><pages>8-21</pages><co_aut>et al.</co_aut></literature><literature><id>4117</id><title>Causes of death in 184 patients with type 1 Gaucher disease from the United States who were never treated with enzyme replaceme</title><author>Weinreb NJ,</author><journal>Blood Cells Mol Dis</journal><year>2016</year><book /><volume>0</volume><number>0</number><pages /><co_aut>Barbouth DS, Lee RE</co_aut></literature><literature><id>4118</id><title>Lung Transplantation in Gaucher Disease: A Learning Lesson in Trying to Avoid Both Scylla and Charybdis</title><author>de Boer GM,</author><journal>Chest</journal><year>2016</year><book /><volume>149</volume><number>1</number><pages>e1-5</pages><co_aut>et al.</co_aut></literature><literature><id>4539</id><title>New Directions in Gaucher Disease</title><author>Horowitz M,</author><journal>Hum Mutat</journal><year>2016</year><book /><volume>37</volume><number>11</number><pages>1121-1136</pages><co_aut>et al.</co_aut></literature><literature><id>4119</id><title>Macrophage-derived soluble CD163 level in young patients with Gaucher disease: relation to phenotypes, disease severity and com</title><author>Adly AA1,</author><journal>Int Immunopharmacol</journal><year>2015</year><book /><volume>24</volume><number>2</number><pages>416-422</pages><co_aut>Ismail EA, Ibraheem TM</co_aut></literature><literature><id>4120</id><title>Imatinib as rescue therapy in a patient with pulmonary hypertension associated with Gaucher disease</title><author>Al-Naamani N,</author><journal>Chest</journal><year>2014</year><book /><volume>146</volume><number>3</number><pages>e81-83</pages><co_aut>et al.</co_aut></literature><literature><id>2581</id><title>Psychological complications of patients with Gaucher disease</title><author>Packman W</author><journal> J Inherit Metab Dis</journal><year>2006</year><book /><volume>29</volume><number>1</number><pages>99-105</pages><co_aut>et al.</co_aut></literature><literature><id>1775</id><title>Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease</title><author>Elstein D</author><journal>J Inherit Metab Dis</journal><year>2004</year><book /><volume>27</volume><number>6</number><pages>757-766</pages><co_aut>et al.</co_aut></literature><literature><id>1507</id><title>A neurological symptom survey of patients with type I Gaucher disease</title><author>Pastores GM</author><journal>J Inherit Metab Dis</journal><year>2003</year><book /><volume>26</volume><number>7</number><pages>641-645</pages><co_aut>et al.</co_aut></literature><literature><id>1776</id><title>Miglustat</title><author>McCormack PL</author><journal>Drugs</journal><year>2003</year><book /><volume>63</volume><number>22</number><pages>2427-2434</pages><co_aut>Goa KL</co_aut></literature><literature><id>866</id><title>[Enzyme replacement therapy: a new treatment concept in Gaucher disease]</title><author>Beck M</author><journal>Wien Klin Wochenschr</journal><year>1997</year><book /><volume>109</volume><number>0</number><pages>81-85</pages><co_aut>et al.</co_aut></literature><literature><id>507</id><title>Effective treatment of painful bone crises in type I Gauchers disease with high dose prednisolone</title><author>Cohen IJ</author><journal>Arch Dis Child</journal><year>1996</year><book /><volume>75</volume><number>0</number><pages>218-222</pages><co_aut>et al.</co_aut></literature><literature><id>539</id><title>Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase</title><author>Kaplan P</author><journal>J Pediatr</journal><year>1996</year><book /><volume>129</volume><number>0</number><pages>149-153</pages><co_aut>et al.</co_aut></literature><literature><id>867</id><title>Current issues in enzyme therapy for Gaucher disease</title><author>Grabowski GA</author><journal>Drugs</journal><year>1996</year><book /><volume>52</volume><number>0</number><pages>159-167</pages><co_aut /></literature><literature><id>161</id><title>Gaucher disease</title><author>Beutler E</author><journal>The metabolic and molecular bases of inherited disease, 7/e; Editors: C.R.Scriver, A.L.Beaudet, W.S.Sly, D.Valle; McGraw-Hill Inc.</journal><year>1995</year><book /><volume>2</volume><number>86</number><pages>2641-2670</pages><co_aut>Grabowski GA</co_aut></literature><literature><id>307</id><title>High frequency of the 1226 mutation for type I Gaucher disease among Ashkenazi jewish population</title><author>Zimran A</author><journal>Am J Hum Genet</journal><year>1991</year><book /><volume>49</volume><number>0</number><pages>855</pages><co_aut>et al.</co_aut></literature></Literatures></Disease>